Immunosuppressant diterpene compound

An immunosuppressant compound is produced having the structure: or a mirror image thereof, wherein X1 is 2,2-dimethylvinyl and X2 and X3 together are =CH2; or X1 is 2,2-dimethyloxiranyl, and X2 and X3 together are -0-CH2-; or X1 is 1,2-dihydroxy-2-methyl-propyl, X2 is -CH2OH, and X3 is OH; or X1 is 2-hydroxy-2-methylpropyl, X2 is H, and X3 is CH2OH; or X1 is COOR, and X2 and X3 together are =O, where R is a lower alkyl, phenyl, or benzyl group; or X1 is 2-methylpropyl, X2 is H, and X3 is CH3. The compound can be produced by culturing Fusarium subglutinans f. sp. tripterygii ATCC 74358 isolated from the stems of Tripterygium wilfordii. A pharmaceutical composition for immunosuppression therapy is prepared containing the compound and a pharmaceutically acceptable vehicle. An immunosuppressant compound is produced having the structure: or a mirror image thereof, wherein X1 is 2,2-dimethylvinyl and X2 and X3 together are =CH2; or X1 is 2,2-dimethyloxiranyl, and X2 and X3 together are -0-CH2-; or X1 is 1,2-dihydroxy-2-methyl-propyl, X2 is -CH2OH, and X3 is OH; or X1 is 2-hydroxy-2-methylpropyl, X2 is H, and X3 is CH2OH; or X1 is COOR, and X2 and X3 together are =O, where R is a lower alkyl, phenyl, or benzyl group; or X1 is 2-methylpropyl, X2 is H, and X3 is CH3. The compound can be produced by culturing Fusarium subglutinans f. sp. tripterygii ATCC 74358 isolated from the stems of Tripterygium wilfordii. A pharmaceutical composition for immunosuppression therapy is prepared containing the compound and a pharmaceutically acceptable vehicle.